Pfizer Inc. maintained sales forecasts for the company’s pandemic products on May 3 after a series of hikes to revenue projections for its COVID-19 vaccine in 2021, in a sign that dizzying growth has slowed.
Merck makes waves in Q1 2022 with COVID-19 treatment, cancer portfolio
Breakthrough Therapy Designation, Business, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, Earnings per share (EPS), Financials, Forecasts, Keytruda, Market Share, Merck, Pneumococcal Conjugate Vaccines, Pneumococcal Vaccines, Sales, TherapeuticsMerck announced the company’s Q1 2022 results, reporting year-over-year revenue growth of 50 percent from continuing operations, with worldwide sales increasing to $15.9 billion. As anticipated, Merck’s COVID-19 antiviral treatment Lagevrio (molnupiravir) played a role in the company’s robust sales.
The World Health Organization indicated support for Pfizer’s Paxlovid and is also reversing a previous decision on using Gilead Sciences’ antiviral remdesivir, now recommending the medication in cases of mild to moderate COVID-19 severity.
AstraZeneca’s Phase III Provent trial results showed a statistically significant 77 percent decrease in a patient’s likelihood of developing symptomatic COVID-19 when proactively treated with Evusheld. Additionally, results were announced by Clover Biopharmaceuticals for the Phase II/III Spectra global study investigating the efficacy of the SCB-2019 (CpG 1018/Alum) vaccine booster in patients that have previously developed a COVID-19 infection.
Worldwide demand for Pfizer Inc.’s oral COVID-19 antiviral treatment Paxlovid has been unexpectedly light due to complicated eligibility requirements, reduced testing and potential for drug interactions, a Reuters review of data and interviews with experts found.
Chinese herbal supplement joins list of disavowed COVID-19 therapies
Approvals (China), China Food and Drug Administration, China National Medical Products Administration (NMPA), China's National Medical Products Administration, COVID-19 Therapeutic, COVID-19 Therapies, Forbes, Global Times, Herbal Medications, Herbal Remedies, National Healthcare Security Administration (NHSA) (China), Studies, The China Food and Drug AdministrationThe Chinese government halted the recommendation of an herbal supplement used as a traditional Chinese treatment for mild cases of COVID-19.
U.S. FDA extends review of Biologics License Application for REGEN-COV (casirivimab and imdevimab) for treatment and prophylaxis of COVID-19
Biologics License Application (BLA), Coronavirus Disease (COVID-19) Pandemic, COVID-19 Therapeutic, COVID-19 Therapeutics, COVID-19 Therapies, FDA, Pandemics, Regeneron Pharmaceuticals, TherapeuticsThe U.S. Food and Drug Administration extended by three months the regulatory agency’s review of the Biologics License Application (BLA) for Regeneron Pharmaceuticals Inc.’s REGEN-COV (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals.
Roche Says U.S. FDA Grants Priority Review to Actemra for COVID-19
Business, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19), COVID-19 antibody drugs, COVID-19 antibody therapy, COVID-19 Therapeutic, COVID-19 therapeutic candidates, COVID-19 Therapeutics, COVID-19 Therapies, FDA, Priority Review, R&D, Research & Development, TherapeuticsThe U.S. Food and Drug administration granted priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalized adults.
Companies Making the Biggest Bucks from COVID-19 Therapeutics Sales
Analysts, Antivirals, Bamlanivimab (LY-CoV555), Biopharma Companies, Business, Coronavirus Disease 2019 (COVID-19), COVID-19 Antibodies, COVID-19 Therapeutic, Deals, Eli Lilly, Etesevimab (Lilly), Gilead, Investors, Merck, Molnupiravir, Omicron (B.1.1.529) (South Africa), Paxlovid, Pfizer, REGEN-COV (casirivimab and imdevimab), Regeneron Pharmaceuticals, Remdesivir, Sales, Therapeutics, U.S. governmentAlthough the COVID-19 pandemic has hit companies unevenly, some biopharma firms that have produced new drugs or vaccines against the disease have shown big spikes in drug sales. BioSpace reviewed five companies that produced non-vaccine treatments for COVID-19.
Gilead Sciences Inc.’s COVID-19 drug remdesivir during 2021 overtook AbbVie Inc.’s 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc., a purchasing group used by about half the nation’s hospitals.